^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Melanoma
    Drug:lerapolturev (PVS-RIPO) (Immunostimulant, Dendritic cell activator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Istari Oncology Press Release
    Title:

    Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma

    Published date:
    06/14/2021
    Excerpt:
    ...Istari Oncology, Inc., a clinical-stage biotechnology company...announced today the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PVSRIPO for the improved survival in patients with advanced melanoma who have disease progression after anti-PD-1/anti-PD-L1 therapy.